Selective RET inhibitors (SRIs) have durable activity in RET fusion-positive lung cancers. Insidious side-effects may emerge with long-term use. This is the first systematic analysis of intestinal lymphangiectasia (IL), an underrecognized disorder characterized by dilated intestinal lacteals and potential lymph leakage, in this population.
Journal of Thoracic Oncology (JTO) published a clinical update in Oncology on 31 Mar 2026.
The item focuses on Brief Report: Intestinal Lymphangiectasia with Selpercatinib and Pralsetinib Treatment.
Review the original article for the full source wording and details.